GlassScriptPhysician profile
Mathula Thangarajh
NPI 1154508968
$46,885.53
in general payments reported to CMS, 2019-2025
9 companies · $2,426 in 2025
The $2,426 reported for 2025 was more than what 81% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,305 · 2021: $7,913 · 2022: $4,448 · 2023: $8,718 · 2024: $18K · 2025: $2,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $16K · Travel and Lodging: $6,497 · Consulting Fee: $5,472 · Food and Beverage: $1,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $15,713.50 |
| Travel and Lodging | $6,496.93 |
| Consulting Fee | $5,472.38 |
| Food and Beverage | $1,536.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ns Pharma, INC. | $22,610.04 | 2021-2025 | Viltepso |
| Sarepta Therapeutics, INC. | $8,486.29 | 2019-2024 | |
| Catalyst Pharmaceuticals, INC. | $6,017.77 | 2024-2025 | |
| Biogen, INC. | $4,129.64 | 2022-2024 | Spinraza |
| Ptc Therapeutics, INC. | $3,412.50 | 2021 | |
| Itf Therapeutics LLC | $1,800.00 | 2024 | |
| Ucb, INC. | $207.69 | 2024 | Rystiggo |
| Genentech USA, INC. | $143.63 | 2023 | Evrysdi |
| Argenx US, INC. | $77.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathula Thangarajh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.